Denufosol tetrasodium Inhalation Solution

( DrugBank: Denufosol / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
299	嚢胞性線維症	9

299. 嚢胞性線維症

臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

trials per page:

Showing 1 to 9 of 9 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01181622 (ClinicalTrials.gov)	August 2010	12/8/2010	A Safety and Tolerability Study of Denufosol in 2-4 Year Olds	A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 7-Day Safety ...	Cystic Fibrosis	Drug: denufosol tetrasodium Inhalation Solution;Drug: 0.9% w/v sodium chloride solution	Merck Sharp & Dohme Corp.	NULL	Completed	2 Years	4 Years	Both	25	Phase 2	United States
2	NCT00846781 (ClinicalTrials.gov)	February 2009	18/2/2009	Study 08-114 Open-label Extension of Study 08-110 - A Multi-Center Study of Denufosol Tetrasodium In ...		Cystic Fibrosis	Drug: Denufosol tetrasodium Inhalation Solution	Merck Sharp & Dohme Corp.	NULL	Terminated	5 Years	N/A	Both	308	Phase 3	United States;Australia;Canada;New Zealand
3	NCT00625612 (ClinicalTrials.gov)	February 2008	12/2/2008	Study of Denufosol Tetrasodium Inhalation Solutionin Patients With Cystic Fibrosis (CF) Lung Disease ...	A Phase 3, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group ...	Cystic Fibrosis	Drug: Denufosol Tetrasodium (INS37217) Inhalation Solution;Drug: Placebo	Merck Sharp & Dohme Corp.	NULL	Completed	5 Years	N/A	Both	466	Phase 3	United States;Australia;Canada;New Zealand
4	NCT00425165 (ClinicalTrials.gov)	July 2007	19/1/2007	Study of Denufosol Inhalation Solutionin Patients With Mild to Moderate Cystic Fibrosis Lung Disease ...	A Randomized, Double-Blind, Two Way Crossover Evaluation of the Effects of a Single Dose of Denufoso ...	Cystic Fibrosis	Drug: denufosol tetrasodium (INS37217) Inhalation Solution	Merck Sharp & Dohme Corp.	NULL	Terminated	10 Years	N/A	Both	6	Phase 2	United States
5	NCT00357279 (ClinicalTrials.gov)	July 2006	25/7/2006	Study of Denufosol Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease	A Multi-Center, Double-Blind, Placebo-Controlled Randomized, Efficacy and Safety Study of Denufosol ...	Cystic Fibrosis	Drug: denufosol tetrasodium(INS37217) Inhalation Solution;Drug: Placebo - 0.9% w/v sodium chloride s ...	Merck Sharp & Dohme Corp.	NULL	Completed	5 Years	N/A	Both	352	Phase 3	United States;Canada
6	NCT00130182 (ClinicalTrials.gov)	August 2005	11/8/2005	A Study in Pediatric Patients With Cystic Fibrosis Lung Disease	A Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of Denufosol Tetrasodium(INS37217) Inha ...	Cystic Fibrosis	Drug: denufosol tetrasodium (INS37217)	Merck Sharp & Dohme Corp.	NULL	Completed	5 Years	7 Years	Both	13	Phase 2	United States
7	NCT00103714 (ClinicalTrials.gov)	January 2005	14/2/2005	Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung Disease	A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of Denufosol Tetrasodium( ...	Cystic Fibrosis	Drug: denufosol tetrasodium (INS37217)	Merck Sharp & Dohme Corp.	NULL	Completed	8 Years	50 Years	Both	72	Phase 2	United States
8	NCT00056147 (ClinicalTrials.gov)	April 2003	6/3/2003	Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease	Multi-Center, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of INS37217 Inhalation Solu ...	Cystic Fibrosis	Drug: denufosol tetrasodium (INS37217)	Merck Sharp & Dohme Corp.	Cystic Fibrosis Foundation Therapeutics	Completed	8 Years	50 Years	Both	90	Phase 2	United States
9	NCT00034515 (ClinicalTrials.gov)	June 2001	29/4/2002	A Study in Adult and Pediatric Patients With Cystic Fibrosis	Ph 1b/2a Study to Assess Levels of INS37217 and Placebo Treatment With Maximum Tolerated Dose Admini ...	Cystic Fibrosis	Drug: denufosol tetrasodium (INS37217) Inhalation Solution	Merck Sharp & Dohme Corp.	NULL	Completed	5 Years	N/A	Both	63	Phase 1/Phase 2	United States

First Previous1Next Last